Home › Carcinoma a cellule squamose della testa e del collo › North Carolina
Studi clinici su Carcinoma a cellule squamose della testa e del collo nello stato di North Carolina
27 studi su Carcinoma a cellule squamose della testa e del collo cercano partecipanti presso sedi nello stato di North Carolina.
Città nello stato di North Carolina
Testo ufficiale dello studio (inglese)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0118, Durham
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06788990Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06589804Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07360314A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 1
Età da 18 a 74 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Carolina Cancer Research Center, Wilson
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Cancer Institute, Charlotte
In reclutamentoFase 3
Età 60 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04892173A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06385080Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Cone Health Cancer Center, Greensboro
- Annie Penn Memorial Hospital, Reidsville
In reclutamentoFase 2
Età da 18 a 79 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT04671667Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT05267626Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT02734537ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT05059444A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- Carolina BioOncology Institute /ID# 272380, Huntersville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07241039Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- e altri 9
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06532279Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 lug 2026 · NCT04375384Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT06993844Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT05005403Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Duke Cancer Center /ID# 251975, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT04777994Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 apr 2026 · NCT04564989Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 feb 2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT06778863A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 gen 2026 · NCT06999187Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- Duke University Medical Center, Durham
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 dic 2025 · NCT05793151A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Levine Cancer Institute, Charlotte
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 ago 2025 · NCT04429542Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.